IJC Heart and Vasculature最新文献

{"title":"High-sensitivity C-reactive protein is associated with altered cardiac structure and function in psoriasis: The PSOCADIA study","authors":"Maria Dons ,&nbsp;Morten Sengeløv ,&nbsp;Kristoffer Grundtvig Skaarup ,&nbsp;Niklas Dyrby Johansen ,&nbsp;Mats C.H. Lassen ,&nbsp;Sofie Bøgh-Sørensen ,&nbsp;Julie I.H. Borchsenius ,&nbsp;Filip Soeskov Davidovski ,&nbsp;Nino E. Landler ,&nbsp;Christoffer V. Nissen ,&nbsp;Peter Riis Hansen ,&nbsp;Brittany N. Weber ,&nbsp;Claus Zachariae ,&nbsp;Lone Skov ,&nbsp;Tor Biering-Sørensen","doi":"10.1016/j.ijcha.2025.101832","DOIUrl":"10.1016/j.ijcha.2025.101832","url":null,"abstract":"<div><h3>Background</h3><div>High sensitivity C-reactive protein (hsCRP) is a biomarker of systemic inflammation that may be associated with cardiovascular risk in psoriasis. We assessed the relationship between hsCRP levels and cardiac structure and function in a large cross-sectional cohort study of individuals with psoriasis.</div></div><div><h3>Methods</h3><div>Adults with psoriasis underwent hsCRP testing and transthoracic echocardiography. Myocardial dysfunction was defined as left ventricular ejection fraction &lt; 50 % and/or global longitudinal strain (GLS) &lt; 16 %. Diastolic dysfunction followed standard echocardiographic guidelines. Associations between hsCRP tertiles, cardiometabolic risk factors, and cardiac structure and function were evaluated. Logistic regression assessed odds of myocardial dysfunction with hsCRP &gt; 2 mg/L.</div></div><div><h3>Results</h3><div>972 adults with psoriasis were prospectively included (median age 54 years, 44.9 % women, 75.2 % moderate-to-severe psoriasis). Median hsCRP was 1.14 mg/L. Lower hsCRP levels were linked to greater biologic therapy use. Higher hsCRP was associated with older age, female sex, increased body mass index, and greater cardiometabolic risk factor burden.</div><div>The highest hsCRP tertile had greater rates of myocardial dysfunction (28.8 %) and diastolic dysfunction (31.3 %) compared to the lowest tertile (17.6 % and 21.8 %, respectively, p &lt; 0.05 for both). After multivariable adjustment, increasing hsCRP was associated with impaired GLS and LVEF, and an hsCRP &gt; 2 mg/L was independently associated with a 45 % increased odds of myocardial dysfunction (OR 1.45, 95 % CI: 1.02 – 2.07, p = 0.042).</div></div><div><h3>Conclusions</h3><div>In psoriasis, elevated hsCRP was independently associated with impaired systolic function, reflected by reduced GLS and LVEF. These findings suggest systemic inflammation may be involved in early myocardial dysfunction in this population.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"61 ","pages":"Article 101832"},"PeriodicalIF":2.5,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145465379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrophage Phospholipase D3 promotes atherosclerosis via exacerbating foam cell formation and inducing inflammatory responses","authors":"Teng Li ,&nbsp;Xiaobao Gu ,&nbsp;Xiangyang Yin ,&nbsp;Pengbo Zhai ,&nbsp;Hongxu Yan ,&nbsp;Zixun Wang ,&nbsp;Yang Li ,&nbsp;Bing Wang","doi":"10.1016/j.ijcha.2025.101834","DOIUrl":"10.1016/j.ijcha.2025.101834","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerosis is a chronic inflammatory disease and a major cause of global morbidity and mortality. Phospholipase D3 (PLD3) has been reported to be elevated in atherosclerotic plaques, yet its functional role and molecular mechanisms remain unclear. This study investigated the role of PLD3 in atherosclerosis.</div></div><div><h3>Methods</h3><div>Single-cell RNA sequencing of human atherosclerotic tissues was analyzed to define PLD3 expression. Validation was performed in ApoE^-/- mice and THP-1-derived foam cells by qRT-PCR and western blotting. Lentiviral-mediated PLD3 knockdown was followed by oxidized LDL (ox-LDL) stimulation. Lipid accumulation and uptake were assessed by Oil Red O, BODIPY, and DiI-ox-LDL assays, while inflammatory cytokines were quantified by qRT-PCR. RNA sequencing was conducted to explore downstream mechanisms.</div></div><div><h3>Results</h3><div>PLD3 expression was markedly upregulated in atherosclerotic lesions and enriched in plaque macrophages, with diagnostic value confirmed by ROC analysis. In vitro, ox-LDL induced PLD3 upregulation in THP-1 macrophages. PLD3 silencing reduced lipid accumulation and uptake through downregulation of CD36, while concurrently decreasing IL-1β and TNF-α expression. Mechanistically, PLD3 deficiency suppressed NF-κB pathway activation.</div></div><div><h3>Conclusion</h3><div>PLD3 is highly expressed in plaque macrophages and promotes atherosclerosis by enhancing CD36-mediated lipid accumulation and activating NF-κB–driven inflammation. These findings identify PLD3 as a potential therapeutic target for atherosclerotic disease.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"61 ","pages":"Article 101834"},"PeriodicalIF":2.5,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145416939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of cardiovascular-kidney-metabolic syndrome staging on clinical outcomes and management of acute pulmonary embolism: A comprehensive analysis","authors":"Shay Zvi Cherevatsky ,&nbsp;Marlon V. Gatuz ,&nbsp;Adam Folman ,&nbsp;Maguli S. Barel ,&nbsp;Rami Abu-Fanne ,&nbsp;Dmitry Abramov ,&nbsp;Mamas A. Mamas ,&nbsp;Ariel Roguin ,&nbsp;Ofer Kobo","doi":"10.1016/j.ijcha.2025.101831","DOIUrl":"10.1016/j.ijcha.2025.101831","url":null,"abstract":"<div><h3>Background</h3><div>Pulmonary embolism (PE) is a life-threatening condition with high morbidity and mortality rates. Cardiovascular-Kidney-Metabolic (CKM) syndrome, representing a complex interplay of cardiovascular disease, kidney dysfunction, and metabolic disorders, may significantly impact PE outcomes. This study investigates the influence of CKM syndrome staging on clinical outcomes and management strategies in acute PE patients.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed 725,725 adult patients hospitalized with a primary diagnosis of PE between 2016 and 2019 using the National Inpatient Sample database. Patients were categorized into five CKM groups (0,1,2/3,4a, 4b) based on staging criteria. Multivariable logistic regression models were used to assess the relationship between in-hospital outcomes and CKM stages.</div></div><div><h3>Results</h3><div>As CKM stages advanced, patients exhibited distinct profiles characterized by older age, male predominance and a higher prevalence of comorbidities. Multivariate analysis revealed that advanced CKM stages were less likely to receive invasive treatments (systemic thrombolysis: aOR 0.86, 95 % CI 0.81–0.92, p &lt; 0.001) but had higher odds of adverse outcomes, including MACCE (aOR 1.53, 95 % CI 1.45–1.60, p &lt; 0.001), mortality (aOR 1.33, 95 % CI 1.25–1.41, p &lt; 0.001), and major bleeding (aOR 1.15, 95 % CI 1.08–1.23, p &lt; 0.001). All odds ratios were computed using CKM stage 0 as the reference group.</div></div><div><h3>Conclusion</h3><div>CKM syndrome staging significantly impacts clinical outcomes and management strategies in patients with PE. Advanced CKM stages are associated with higher risks of adverse events, including increased mortality and major bleeding complications. Paradoxically, these high-risk patients were less likely to receive invasive treatments, highlighting a critical gap in care.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"61 ","pages":"Article 101831"},"PeriodicalIF":2.5,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145416825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Middle to long-term outcomes and pathological changes of implanted expanded polytetrafluoroethylene valved conduits","authors":"Yixuan Cai ,&nbsp;Yaping Shan ,&nbsp;Gang Chen,&nbsp;Yaping Mi,&nbsp;Hui Zhong,&nbsp;Ming Ye,&nbsp;Huifeng Zhang","doi":"10.1016/j.ijcha.2025.101829","DOIUrl":"10.1016/j.ijcha.2025.101829","url":null,"abstract":"<div><h3>Objectives</h3><div>This study evaluated the mid to long-term outcomes of expanded polytetrafluoroethylene valved conduits and preliminarily explored the reasons for conduit failure.</div></div><div><h3>Methods</h3><div>The study included patients who received reconstruction with ePTFE valved conduits between June 2014 and March 2025. Echocardiography was used to evaluate the conduit function. Histopathological staining was applied to demonstrate the details of the failure conduits.</div></div><div><h3>Results</h3><div>104 patients had a median age of 90 months (interquartile range, 44.25–144 months) and a median follow-up of 48 months (IQR, 16–54.25 months). 4 early deaths (3.8 %) and 1 late death (1.0 %) occurred. 28 conduits (26.9 %) were detected with dysfunction, with 10 (9.6 %) progressing to failure. Infective endocarditis only occurred in 2 patients (1.9 %). 7 patients (6.7 %) received re-interventions, including 2 percutaneous interventions, 1 replacement after percutaneous intervention, and 4 direct replacements. Pathological staining showed no thrombus formation, but calcification on the valve junction. The valved conduit exhibited insufficient endothelialization, accompanied by the infiltration of inflammatory cells and remarkable neointimal hyperplasia.</div></div><div><h3>Conclusions</h3><div>The application of the ePTFE valved conduit presented low mortality rate and relatively appreciable conduit function. Conduit stenosis was the main cause of failure, characterized by calcification and neointimal hyperplasia, and might be related to inflammatory response and material damage.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"61 ","pages":"Article 101829"},"PeriodicalIF":2.5,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145416823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidimensional optimization of stent design for endothelial shear stress regulation: Geometric structuring, surface functionalization strategies to mitigate thrombosis and restenosis","authors":"Mengyuan Che ,&nbsp;Liuliu Feng ,&nbsp;Xinbing Liu ,&nbsp;Liangfeng Zhao ,&nbsp;Suying Zhou ,&nbsp;Xinyu Zhong ,&nbsp;Lingsen You ,&nbsp;Yu Wang","doi":"10.1016/j.ijcha.2025.101830","DOIUrl":"10.1016/j.ijcha.2025.101830","url":null,"abstract":"<div><div>The occurrence of in-stent restenosis (ISR) is closely associated with abnormal distribution of endothelial shear stress (ESS), and optimizing stent design is crucial for improving patient prognosis. This review aims to comprehensively explore how stent design parameters—including geometric structure and surface functionalization—influence neointimal hyperplasia and thrombosis by modulating ESS, while also summarizing the latest technological strategies. A detailed discussion is provided on the design evolution from traditional coronary stents to for non-coronary arteries (cerebral aneurysm) micro-woven stents, analyzing the mechanisms by which factors such as streamlined profiles, reduced strut thickness, and optimized spacing improve hemodynamics. Furthermore, the article critically evaluates the advantages and current limitations of cutting-edge technologies such as computational fluid dynamics (CFD)-based optimization and endothelialization-promoting functional coatings. We conclude that multidimensional stent design optimization represents a future trend in regulating ESS and suppressing restenosis. Future research should focus on integrating personalized design with highly biocompatible materials to advance the clinical translation of next-generation vascular stents.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"61 ","pages":"Article 101830"},"PeriodicalIF":2.5,"publicationDate":"2025-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145416940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factor XIII and cardiovascular disease: biomarker, culprit or victim in acute myocardial infarction outcomes?","authors":"Florian Bruns ,&nbsp;Dobromir Dobrev ,&nbsp;Anke C. Fender","doi":"10.1016/j.ijcha.2025.101827","DOIUrl":"10.1016/j.ijcha.2025.101827","url":null,"abstract":"","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"61 ","pages":"Article 101827"},"PeriodicalIF":2.5,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent highlights from the International Journal of Cardiology: Heart & Vasculature: Valvular heart disease","authors":"Francesco Pelliccia,&nbsp;Artur Dziewierz,&nbsp;Marco Zimarino,&nbsp;Dobromir Dobrev","doi":"10.1016/j.ijcha.2025.101828","DOIUrl":"10.1016/j.ijcha.2025.101828","url":null,"abstract":"","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"61 ","pages":"Article 101828"},"PeriodicalIF":2.5,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary artery calcium on lung cancer screening-CT: An opportunity to optimize cardiovascular disease risk reduction","authors":"Bethlehem Mengesha ,&nbsp;Keren Mbondo Kasuku ,&nbsp;Toby David Small ,&nbsp;Marcella Cabral Caires ,&nbsp;Habibat Garuba ,&nbsp;Angeline Law ,&nbsp;Christopher Johnson ,&nbsp;David Ian Paterson ,&nbsp;Carole Dennie ,&nbsp;Elena Pena ,&nbsp;Benjamin JW Chow ,&nbsp;Gary R Small","doi":"10.1016/j.ijcha.2025.101826","DOIUrl":"10.1016/j.ijcha.2025.101826","url":null,"abstract":"<div><h3>Background</h3><div>In lung cancer screening trials, mortality from cardiovascular disease occurs at similar rates to lung cancer deaths. Survival following lung cancer screening could be optimized if atherosclerosis prevention was targeted. Thus, we sought to determine whether there was potential for improvement in rates of cardiovascular risk reduction therapy based upon coronary artery calcium and cardiovascular risk assessment.</div></div><div><h3>Methods</h3><div>Clinical lung cancer screening-CT reports, lipid lowering therapy and clinical demographics were retrieved from the electronic medical record in the first consecutive 1486 cases without known coronary artery disease from the Ontario High Risk Lung Cancer Screening Pilot program. Lung cancer screening CT images were reviewed for presence and extent of coronary artery calcium.</div></div><div><h3>Results</h3><div>Coronary artery calcium was detected in 83 % and was reported in 63 %. Lipid lowering was prescribed in 60 % of cases whose coronary artery calcium was reported versus 45 % of cases when coronary artery calcium was unreported (p &lt; 0.001). On multivariable analysis, increased Framingham risk score (OR 2.31 95 % CI 1.73–2.31, p &lt; 0.001) and reported coronary artery calcium (OR 1.53 95 % CI 1.22–1.92, p &lt; 0.001) were associated with lipid lowering therapy. Additional cardiovascular risk lowering could be achieved in 21 % using coronary artery calcium and in 44 % with further consideration of clinical risk.</div></div><div><h3>Conclusions</h3><div>In lung cancer screened patients, cardiovascular risk reduction could be optimized significantly by the opportunistic use of coronary artery calcium and clinical assessment. Appropriate cardiovascular risk reduction could attenuate the high prevalence of cardiovascular deaths in these individuals and improve overall survival.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"61 ","pages":"Article 101826"},"PeriodicalIF":2.5,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of complete revascularization with safety and outcomes in elderly patients with multi-vessel coronary artery disease: a systematic review and meta-analysis","authors":"David T. Zhang ,&nbsp;Matt Raven ,&nbsp;Manasa Dondapati ,&nbsp;Ravi Masson ,&nbsp;Puja B. Parikh ,&nbsp;Travis Bench ,&nbsp;John P. Reilly ,&nbsp;Michael Tao","doi":"10.1016/j.ijcha.2025.101825","DOIUrl":"10.1016/j.ijcha.2025.101825","url":null,"abstract":"<div><h3>Background</h3><div>The utility of complete revascularization has been well defined in young patients with acute coronary syndrome (ACS) and multivessel coronary artery disease (CAD). However, the clinical benefit in elderly patients remains unclear with current literature has yielded conflicting results. This meta-analysis aims to evaluate the association of complete versus culprit-only coronary revascularization with mortality in elderly patients with multivessel CAD.</div></div><div><h3>Methods</h3><div>A literature search was conducted for studies reporting on outcomes after complete versus culprit-only revascularization in elderly patients with multivessel CAD presenting with ACS. The primary endpoint was all-cause mortality. The main secondary endpoint was cardiovascular (CV) mortality. The search included the following databases: PubMed, EMBASE, and Web of Science. The search was not restricted to time or publication status.</div></div><div><h3>Results</h3><div>14 studies with 11,994 elderly patients (7,236 with culprit-only, 4,758 with complete revascularization) met inclusion criteria. Mean follow-up duration was 29.0 months (range 12–56 months), mean age was 79.5 years old, 56.9% of patients were men, and mean left ventricular ejection fraction was 54.3%. Patients who underwent complete revascularization had significantly lower all-cause and CV mortality compared to culprit-only revascularization (OR 1.75, 95% CI 1.40–2.18; p &lt; 0.001; OR 1.75, 95% CI 1.14–2.68; p = 0.01). Subgroup analysis demonstrated this association to be statistically significant for studies with cohorts presenting with non-ST segment elevation myocardial infarction (NSTEMI) and mixed cohorts that included NSTEMI and ST segment elevation myocardial infarction (STEMI) patients. However, there was no significant difference in risk of all-cause mortality with complete versus culprit-only revascularization in studies of only STEMI patients (OR 1.03, 95% CI 0.61–1.72; p = 0.92).</div></div><div><h3>Conclusion</h3><div>Complete coronary revascularization is associated with lower risk of all-cause and CV mortality in elderly patients with multivessel CAD presenting with NSTEMI. However, there does not appear to be a difference in outcomes in patients presenting with STEMI.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"61 ","pages":"Article 101825"},"PeriodicalIF":2.5,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thoracic endovascular aortic repair for traumatic and non-traumatic rupture of the descending thoracic aorta: A 15-year single-centre experience","authors":"Ricarda Berkenheide ,&nbsp;Rolf Alexander Jánosi ,&nbsp;Fadi Al-Rashid ,&nbsp;Daniel Messiha ,&nbsp;Konstantinos Tsagakis ,&nbsp;Christos Rammos ,&nbsp;Sharaf-Eldin Shehada ,&nbsp;Payam Akhyari ,&nbsp;Thomas Schlosser ,&nbsp;Tienush Rassaf ,&nbsp;Julia Lortz","doi":"10.1016/j.ijcha.2025.101818","DOIUrl":"10.1016/j.ijcha.2025.101818","url":null,"abstract":"<div><h3>Background</h3><div>Ruptures of the descending thoracic aorta are life-threatening emergencies with traumatic and non-traumatic causes. Thoracic endovascular aortic repair (TEVAR) has become a key treatment, but long-term outcome data remain limited. This study aimed to review our experience with TEVAR in patients with traumatic or non-traumatic rupture and identify factors associated with post-TEVAR survival.</div></div><div><h3>Methods</h3><div>Between 2001 and 2016, 56 patients (21 with traumatic rupture and 35 with non-traumatic rupture) underwent TEVAR at the West-German Heart and Vascular Center Essen, Germany. Data examined included demographics, comorbidities, biomarker levels, imaging results, intervention details, complications, and outcomes (30 days and follow-up).</div></div><div><h3>Results</h3><div>Patients with non-traumatic rupture were significantly older and had more cardiovascular comorbidities. Patients with traumatic rupture presented more frequently with hemodynamic shock and mediastinal hematoma (47 %). Left subclavian artery coverage was more common in traumatic rupture (57.1 % vs. 18.2 %). Long-term aortic complications were more frequent in non-traumatic rupture (33.3 % vs. 0 %). Patients with traumatic rupture showed significantly longer survival. The overall 30-day mortality was 14.3 % (4.7 % in traumatic rupture patients vs. 20 % in non-traumatic rupture patients) and long-term mortality was 64.5 % (33.3 % in traumatic rupture patients vs. 84.2 % in non-traumatic rupture patients). Age, hypertension, complications, and the aetiology of aortic rupture significantly affected survival.</div></div><div><h3>Conclusion</h3><div>Patients with traumatic aortic rupture are younger, have healthier vessels, and show better outcomes after TEVAR. This may allow longer follow-up intervals in selected cases, while closer monitoring remains necessary for non-traumatic ruptures.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"61 ","pages":"Article 101818"},"PeriodicalIF":2.5,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145320617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}